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Acetyl-coenzyme A (acetyl-CoA) is a central metabolic intermediate. The abundance of acetyl-CoA in distinct
subcellular compartments reflects the general energetic state of the cell. Moreover, acetyl-CoA concentra-
tions influence the activity or specificity of multiple enzymes, either in an allosteric manner or by altering
substrate availability. Finally, by influencing the acetylation profile of several proteins, including histones,
acetyl-CoA controls key cellular processes, including energy metabolism, mitosis, and autophagy, both
directly and via the epigenetic regulation of gene expression. Thus, acetyl-CoA determines the balance
between cellular catabolism and anabolism by simultaneously operating as a metabolic intermediate and
as a second messenger.Introduction
Acetyl-coenzyme A (acetyl-CoA) is so central for intermediate
metabolism that hypothetical reconstructions of the origin of
life postulate its involvement in ancestral methanotrophic reac-
tions performed by the last common precursor of prokaryotes
(Nitschke and Russell, 2013). From archaebacteria to mamma-
lians, acetyl-CoA occupies a critical position in multiple cellular
processes, as a metabolic intermediate, as a precursor of
anabolic reactions, as an allosteric regulator of enzymatic activ-
ities, and as a key determinant of protein acetylation (Choudh-
ary et al., 2014). Acetyl-CoA is indeed the actual molecule
through which glycolytic pyruvate enters the tricarboxylic acid
(TCA) cycle, is a key precursor of lipid synthesis, and is the
sole donor of the acetyl groups for acetylation (Choudhary
et al., 2014).
Acetyl-CoA is a membrane-impermeant molecule constituted
by an acetyl moiety (CH3CO) linked to coenzyme A (CoA), a de-
rivative of vitamin B5 and cysteine, through a thioester bond (Shi
and Tu, 2015). As thioester bonds are energy rich, the chemical
structure of acetyl-CoA facilitates the transfer of the acetyl moi-
ety to a variety of acceptormolecules, including amino groups on
proteins (Shi and Tu, 2015). Acetylation can occur as a co-trans-
lational event. In this setting, Na acetyltransferases (NATs) trans-
fer an acetyl group from acetyl-CoA to the a-amino group of
the N-terminal residue of the protein (which generally is serine,
alanine, glycine, threonine, valine, or cysteine), once the initiator
methionine has been removed by methionine aminopeptidases.
N-terminal acetylation affects the vast majority of human pro-
teins, determining their stability, localization, and function (Holle-
beke et al., 2012).Nonetheless, acetylation is mostly studied as a post-transla-
tional modification that concerns the Nε amino group of lysine
residues, eliminating their positive charge and increasing sterical
hindrance (Choudhary et al., 2014). Thus, Nε acetylation can alter
the functional profile of a specific protein by influencing its cata-
lytic activity, its capacity to interact with other molecules
(including other proteins), its subcellular localization, and/or its
stability (Choudhary et al., 2014). These effects can directly orig-
inate from the changes in charge and hindrance imposed by Nε
acetylation, or they can reflect (1) the binding of proteins that
contain acetyl-lysine recognition bromodomains (Zeng et al.,
2010) or (2) the occupancy of lysine residues that may have
been subjected to other post-translational modifications,
including ubiquitination, methylation, formylation, and higher-
order acylation reactions (Choudhary et al., 2014).
Nε acetylation can occur through a non-enzymatic mecha-
nism, especially in alkaline environments like the mitochondrial
matrix (Weinert et al., 2014), or can be catalyzed by a diverse
group of lysine acetyltransferases (KATs) (Choudhary et al.,
2014). The human genome encodes no less than 22 distinct
KATs, which possess marked substrate specificity (Davenport
et al., 2014). Many KATs have a relatively high KD (low affinity)
for acetyl-CoA, meaning that physiological fluctuations in the
abundance of acetyl-CoA within the cellular compartment where
such KATs are expressed can affect their catalytic activity. For
instance, KAT2A (also known as GCN5) has a KD for acetyl-
CoA of 0.56 mM and its yeast counterparts of 8.5 mM (Langer
et al., 2002), both of which fall in the concentration range of
acetyl-CoA found in human or yeast cells (Cai et al., 2011; Lee
et al., 2014). Other KATs have a similar affinity for acetyl-CoACell Metabolism 21, June 2, 2015 ª2015 Elsevier Inc. 805
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abundance of acetyl-CoA and CoA (the latter can mediate prod-
uct inhibition). Importantly, the concentration of acetyl-CoA (or
the acetyl-CoA/CoA ratio) does not only determine the enzy-
matic activity of KATs, but also alters their specificity. Thus,
KATs like E1A binding protein p300 (EP300) and CREB binding
protein (CREBBP, best known as CBP) exhibit distinct Hill values
(i.e., different degrees of cooperativity) at varying acetyl-CoA
levels, meaning that their selectivity (i.e., their preference to acet-
ylate distinct lysine residues) changes (Denisov and Sligar, 2012;
Henry et al., 2015).
In response to a series of physiological or pathological condi-
tions, the abundance and/or distribution of acetyl-CoA in distinct
subcellular and/or pericellular compartments changes consider-
ably. Thus, acetyl-CoA can act as a second messenger that re-
lays signals from the extracellular to the intracellular milieu.
This may contribute to the elevated variability in lysine acetyla-
tion patterns encountered in organs and subcellular fractions in
distinct functional states (Lundby et al., 2012).
Here, we discuss the ability of acetyl-CoA to regulate adaptive
responses to homeostatic perturbations by controlling the
equilibrium between catabolic and anabolic reactions as well
as by influencing major cellular processes such as cell cycle pro-
gression, mitosis, autophagy, and regulated cell death (RCD).
Acetyl-CoA: A Central Metabolite
Acetyl-CoA is not only the product of multiple catabolic reac-
tions, but also one of the central substrates for anabolic
metabolism. For illustrative purposes, we will discuss the mito-
chondrial and extramitochondrial metabolism of acetyl-CoA
separately.
Generation of Mitochondrial Acetyl-CoA
In most mammalian cells, acetyl-CoA is predominantly gener-
ated in the mitochondrial matrix by various metabolic circuitries,
namely glycolysis, b-oxidation, and the catabolism of branched
amino acids (Figure 1A).
Glycolysis culminates in the generation of cytosolic pyruvate,
which is imported into mitochondria by the mitochondrial pyru-
vate carrier (MPC), a heterodimer of MPC1 and MPC2 (Herzig
et al., 2012). Mitochondrial pyruvate is decarboxylated to form
acetyl-CoA, CO2, and NADH by the so-called pyruvate dehydro-
genase complex (PDC), a large multicomponent system that in
humans is composed of (1) three proteins that are directly
involved in CoA- and NAD+-dependent pyruvate decarboxyl-
ation, i.e., pyruvate dehydrogenase (lipoamide) (PDH, which in
exists in three isoforms), dihydrolipoamide S-acetyltransferase
(DLAT), and dihydrolipoamide dehydrogenase (DLD); (2) two reg-
ulatory components, i.e., pyruvate dehydrogenase kinase (PDK,
which also exists in four isoforms) and pyruvate dehydrogenase
phosphatase (PDP, a heterodimer involving either of two cata-
lytic subunits and either of two regulatory subunits); and (3)
one non-enzymatic subunit, i.e., pyruvate dehydrogenase com-
plex, component X (PDHX) (Patel et al., 2014). Importantly, both
acetyl-CoA andNADHaswell as ATP allosterically inhibit PDC as
they activate PDK. Conversely, CoA, NAD+, and ADP promote
pyruvate decarboxylation by inhibiting PDK. Finally, acetyl-CoA
acts as a potent allosteric activator of pyruvate carboxylase
(PC), another pyruvate-consuming enzyme that synthesizes
oxaloacetate for anaplerotic reactions (Adina-Zada et al.,806 Cell Metabolism 21, June 2, 2015 ª2015 Elsevier Inc.2012). These regulation circuitries ensure that the products of
glycolysis are employed for ATP generation when cells are in
energy-low conditions (characterized by elevated ADP, NAD+,
and CoA levels), but diverted toward anabolic metabolism
when the energy stores are repleted (characterized by elevated
ATP, NADH, and acetyl-CoA levels).
Alternatively, acetyl-CoA can be generated as the end prod-
uct of b-oxidation. In this case, one among several members of
the acyl-CoA synthetase protein family catalyzes the CoA- and
ATP-dependent conversion of cytosolic free fatty acids into
acyl-CoA. Acyl-CoA is then condensed with L-carnitine to
form acylcarnitine and free CoA, a cytosolic reaction catalyzed
by carnitine palmitoyltransferase 1 (CPT1). Acylcarnitine is im-
ported into mitochondria through the antiporter solute carrier
family 25 (carnitine/acylcarnitine translocase), member 20
(SLC25A20), which exchanges it for free L-carnitine. Finally,
mitochondrial acylcarnitine is reconverted by carnitine palmi-
toyltransferase 2 (CPT2) into L-carnitine (which drives the
so-called ‘‘carnitine shuttle’’) and acyl-CoA, and the latter un-
dergo b-oxidation to generate NADH and acetyl-CoA for use
as direct and indirect, respectively, respiratory substrates
(Rufer et al., 2009).
Branched-chain amino acids (i.e., valine, leucine, and isoleu-
cine) can also be employed to produce acetyl-CoA (Harris
et al., 2005), a molecular circuitry that may depend on the mito-
chondrial deacetylase sirtuin 3 (SIRT3), at least in some tissues
(including the brain, liver, kidney, and skeletal muscles) (Ditten-
hafer-Reed et al., 2015). To this aim, branched amino acids
must be first transaminated to branched-chain a-ketoacids, a
reaction that can be catalyzed by the cytosolic enzyme
branched-chain amino acid transaminase 1 (BCAT1). Upon
import into the mitochondrial matrix via the carnitine shuttle
(see below) (Violante et al., 2013), branched-chain a-ketoacids
are processed via amulti-step reaction comparable to the decar-
boxylation of pyruvate. This irreversible reaction is catalyzed by
the mitochondrial branched-chain a-ketoacid dehydrogenase
(BCKD) complex, a large multicomponent enzymatic system
yielding NADH, acetyl-CoA, and other acyl-CoA thioesters
(which can be processed by b-oxidation or the TCA) as end prod-
ucts (Harris et al., 2005). Of note, somemammalian cells express
a mitochondrial variant of BCAT1 (i.e., BCAT2), which is catalyt-
ically active (Yennawar et al., 2006). However, how branched-
chain amino acids enter the mitochondrial matrix has not been
determined yet.
In addition to these nearly ubiquitous metabolic circuitries,
there are organ-specific pathways for mitochondrial acetyl-
CoA generation. For instance, neurons can employ the ketone
body D-b-hydroxybutyrate to generate acetyl-CoA (Cahill,
2006). This occurs via a three-step reaction involving the
NAD+-dependent oxidation of D-b-hydroxybutyrate to acetoa-
cetate (catalyzed by 3-hydroxybutyrate dehydrogenase, type
1, BDH1), the transfer of CoA from succinyl-CoA to acetoacetate
(catalyzed by 3-oxoacid CoA transferase 1, OXCT1, or OXCT2),
and the CoA-dependent cleavage of acetoacetyl-CoA into two
acetyl-CoA molecules (catalyzed by an enzymatic complex
with acetoacetyl-CoA thiolase activity) (Cahill, 2006). Of note, it
has recently been demonstrated that the acetylation pattern of
mitochondrial proteins, as controlled by SIRT3, is crucial for
mice that respond to starvation to increase the hepatic synthesis
Figure 1. Mitochondrial and Nucleo-Cytosolic Bioenergetic Metabolism of Acetyl-CoA in Mammalian Cells
(A–D) Acetyl coenzyme A (acetyl-CoA) is a key metabolic intermediate. Generally, the majority of cellular acetyl-CoA is generated (A) and consumed (C) in the
mitochondrial matrix, in the context of the oxidative metabolism of glycolytic pyruvate (Pyr), free fatty acids (FFAs), branched-chain amino acids (BCAAs), or
ketone bodies within the tricarboxylic acid (TCA) cycle. Acetyl-CoA can also be generated in the cytosolic compartment (B), where it supports several anabolic
reactions, including lipogenesis, steroidogenesis, and the synthesis of specific amino acids (D). In some malignant cells, the pyruvate dehydrogenase complex
(PDC), ATP citrate lyase (ACLY), and acyl- CoA synthetase short-chain family, member 2 (ACSS2) are also found in the nucleus and produce acetyl-CoA therein.
Of note, both mitochondrial and nucleo-cytosolic acetyl-CoA pools are critically involved in protein acetylation reactions. ACAA2, acetyl-CoA acyltransferase 2;
ACAC, acetyl-CoA carboxylase; ACAD, acyl-CoA dehydrogenase; ACAT1, acetyl-CoA carboxylase 1; ACAT2, acetyl-CoA acetyltransferase 2; Ace, acetate; Ach,
acetaldehyde; ACO1, aconitase 1, soluble; ACSS1, acyl-CoA synthetase short-chain family, member 1; ADH1B, alcohol dehydrogenase IB (class I), beta
polypeptide; ALDH1A1, aldehyde dehydrogenase 1 family, member A1; ALDH2, aldehyde dehydrogenase 2 family; BCAT1, branched chain amino-acid
transaminase 1, cytosolic; BCAT2, branched chain amino-acid transaminase 2, mitochondrial; BCKD, branched-chain a-ketoacid dehydrogenase; BDH1,
3-hydroxybutyrate dehydrogenase, type 1; b-OHB, D-b-hydroxybutyrate; Cit, citrate; CPT1, carnitine palmitoyltransferase 1; CPT2, carnitine palmitoyl-
transferase 2; ECH, enoyl-CoA hydratase; ER, endoplasmic reticulum; Eth, ethanol; FASN, fatty acid synthase; Gln, glutamine; GLS, glutaminase; GLUD1,
glutamate dehydrogenase 1; GOT1, glutamic-oxaloacetic transaminase 1, soluble; HADH, hydroxyacyl-CoA dehydrogenase; HAT, histone acetyltransferase;
HMGCL, 3-hydroxymethyl-3-methylglutaryl-CoA lyase; HMGCR, 3-hydroxy-3-methyl-glutaryl-CoA reductase; HMGCS1, 3-hydroxy-3-methylglutaryl-CoA
synthase 1, HMGCS2, 3-hydroxy-3-methylglutaryl-CoA synthase 2, IDH1, isocitrate dehydrogenase 1; KAT, lysine acetyltransferase; MPC1, mitochondrial
pyruvate carrier 1; MPC2, mitochondrial pyruvate carrier 2; NAT, Na acetyltransferase; NEA, non-enzymatic acetylation; OXCT, 3-oxoacid CoA transferase.
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activating bioenergetic pathways that utilize ketone bodies in
extrahepatic tissues (Dittenhafer-Reed et al., 2015). Hepato-
cytes can also obtain acetyl-CoA from ethanol (Cederbaum,
2012; Lundquist et al., 1962). In this case, ethanol is first con-
verted into acetaldehyde in the cytosol by alcohol dehydroge-
nase IB (class I) beta polypeptide (ADH1B). Acetaldehyde freely
diffuses to the mitochondrial matrix, where it is converted into
acetate by aldehyde dehydrogenase 2 family (ALDH2). Finally,
themitochondrial enzyme acyl-CoA synthetase short-chain fam-
ily, member 1 (ACSS1) employs acetate to produce acetyl-CoA
(Fujino et al., 2001). This metabolic circuitry may explain whyethanol ingestion causes protein acetylation preferentially in he-
patic mitochondria (Fritz et al., 2013).
Generation of Cytosolic Acetyl-CoA
In physiological and normoxic conditions, glycolysis- or b-oxida-
tion-derived mitochondrial acetyl-CoA represents the major
source of cytosolic acetyl-CoA upon transportation (see below).
That said, there are at least two relatively ubiquitous metabolic
circuitries through which cells actually produce acetyl-CoA in
the cytosol (Figure 1B).
First, cytosolic acetyl-CoA can originate from glutamine
reductive carboxylation, especially when glycolysis is blocked
(Yang et al., 2014), in hypoxic conditions (Metallo et al., 2012),Cell Metabolism 21, June 2, 2015 ª2015 Elsevier Inc. 807
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Upon uptake from the extracellular milieu (which is mediated by
various transporters, depending on cell type), cytosolic gluta-
mine is metabolized by glutaminase (GLS) to generate gluta-
mate, which enters mitochondria through the H+-dependent
glutamate/aspartate antiporter solute carrier family 25 (aspar-
tate/glutamate carrier), member 13 (SLC25A13). Mitochondrial
glutamate is converted into a-ketoglutarate (a reaction catalyzed
by glutamate dehydrogenase 2, GLUD2, or glutamic-oxaloacetic
transaminase 2, mitochondrial, GOT2), which undergoes reduc-
tive carboxylation within the TCA cycle to generate citrate.
Finally, citrate can be exported back to the cytosol via the dicar-
boxylate antiporter solute carrier family 25 (mitochondrial carrier;
citrate transporter), member 1 (SLC25A1), and converted into
oxaloacetate and acetyl-CoA by ATP citrate lyase (ACLY) (Zaidi
et al., 2012). Of note, glutamate also can be converted into a-ke-
toglutarate by GLUD1, a cytosolic variant of GLUD2, at least in
some settings (Grassian et al., 2014). Along similar lines, a cyto-
solic form of GOT2 (i.e., GOT1) can catalyze the reversible inter-
conversion of glutamate and oxaloacetate into a-ketoglutarate
and aspartate. Cytosolic a-ketoglutarate can be metabolized
by isocitrate dehydrogenase 1 (IDH1) and aconitase 1 soluble
(ACO1) to generate citrate for acetyl-CoA synthesis by ACLY
(Grassian et al., 2014).
Second, a cytosolic counterpart of ACSS1, i.e., acyl-CoA syn-
thetase short-chain family, member 2 (ACSS2), employs acetate
to produce acetyl-CoA in an ATP-dependent manner (Schug
et al., 2015). Cytosolic acetate can derive from the extracellular
milieu, upon uptake by various members of the monocarboxy-
late transporter protein family (Halestrap and Price, 1999), or it
can be synthesized from ethanol-derived acetaldehyde by a
cytosolic variant of ALDH2, namely aldehyde dehydrogenase 1
family, member A1 (ALDH1A1), at least in hepatocytes (Ceder-
baum, 2012). Although circulating acetate levels are relatively
low in modern humans (as compared to their ancestors, owing
to dietary changes) (Frost et al., 2014), the ACSS2-dependent
conversion of acetate into acetyl-CoA has been shown to be pre-
ponderant in primary and metastatic malignant cells of various
origin (Mashimo et al., 2014), especially in hypoxic conditions
(Kamphorst et al., 2014; Schug et al., 2015). In line with this
notion, hepatocellular carcinomas driven by the expression of
simian virus 40 (SV40) T antigen or by v-myc avianmyelocytoma-
tosis viral oncogene homolog (Myc) overexpression combined
with phosphatase and tensin homolog (Pten) inactivation exhibit
reduced growth rate in Acss2/ mice (Comerford et al., 2014).
Moreover, elevated ACSS2 levels are associated with high tumor
grade and dismal disease outcome in patients with human
gliomas (Mashimo et al., 2014) and triple-negative breast carci-
nomas (Comerford et al., 2014). Thus, themetabolic stress asso-
ciated with malignant transformation and/or tumor progression
(which generally involves decreased nutrient availability and hyp-
oxia) may render cancer cells addicted to ACSS2 activity (which
is non-oncogenic per se) (Galluzzi et al., 2013). Further corrobo-
rating this notion, breast carcinomas often exhibit ACSS2 ampli-
fications (Schug et al., 2015).
Ectopic Acetyl-CoA Generation
Asmalignant cells progress through the S phase of the cell cycle,
functional PDC can translocate from mitochondria to the nu-
cleus, catalyzing the ectopic synthesis of acetyl-CoA from pyru-808 Cell Metabolism 21, June 2, 2015 ª2015 Elsevier Inc.vate (Sutendra et al., 2014). Nuclear PDC levels as well as
histone 3 (H3) acetylation increase upon the administration of
epidermal growth factor (EGF), whereas the inhibition of EGF
receptor (EGFR) signaling limits nuclear PDC accumulation
concomitant with a reduction in H3 acetylation levels. Also, the
inhibition of respiratory complex I with rotenone can promote
the mitochondrio-nuclear relocalization of PDC, a process that
appears to require heat shock 70 kDa protein 1A (HSPA1A)
(Sutendra et al., 2014). However, the exact mechanisms through
which PDC is exported from mitochondria and enters the nu-
cleus remain enigmatic. Since PDK is not detectable within
nuclei (Sutendra et al., 2014), nuclear PDC may be constitutively
derepressed to support histone acetylation and cell cycle
progression. Interestingly, two other acetyl-CoA-generating en-
zymes, namely ACLY and ACSS2, have been localized to the nu-
cleus and linked to cell growth and proliferation (Comerford
et al., 2014; Takahashi et al., 2006; Wellen et al., 2009). Taken
together, these observations suggest that, even though acetyl-
CoA freely diffuses between the cytosol and nucleus, the pro-
duction of acetyl-CoA in the proximity of histones may favor
the activation of epigenetic programs associated with cell
growth (see below).
Metabolic Fate of Mitochondrial Acetyl-CoA
Normally, mitochondrial acetyl-CoA is metabolized within the
TCA to yield NADH, the main substrate for ATP synthesis via
oxidative phosphorylation (Boroughs and DeBerardinis, 2015).
Some cells, however, including hepatocytes, can employ mito-
chondrial acetyl-CoA to synthesize ketone bodies, i.e., acetoa-
cetate, acetone, andD-b-hydroxybutyrate (Newman and Verdin,
2014). This metabolic pathway, which is catalyzed by the
sequential activity of the acetoacetyl-CoA thiolase complex,
3-hydroxy-3-methylglutaryl-CoA synthase 2 (HMGCS2), 3-hy-
droxymethyl-3-methylglutaryl-CoA lyase (HMGCL), and BDH1,
is particularly active in conditions of fasting or caloric restriction,
when the majority of mitochondrial acetyl-CoA derives from
b-oxidation (Figure 1C) (Newman and Verdin, 2014). Liver-
derived ketone bodies enter the circulation and are readily taken
up by neurons and cardiomyocytes, which employ them to pro-
duce ATP upon reconversion to acetyl-CoA and entry in the TCA
(Cotter et al., 2013). Of note, D-b-hydroxybutyrate acts as an
endogenous inhibitor of class I histone deacetylases, i.e.,
HDAC1, HDAC2, and HDAC3 (Shimazu et al., 2013). This may
explain why fasting and caloric restriction increase global his-
tone acetylation in some mouse tissues, particularly the liver
and kidney (Donohoe et al., 2012; Shimazu et al., 2013).
Metabolic Fate of Cytosolic Acetyl-CoA
Cytosolic acetyl-CoA is the precursor of multiple anabolic reac-
tions that underlie the synthesis of fatty acids and steroids, as
well as specific amino acids including glutamate, proline, and
arginine (Figure 1D). The rate-limiting step of lipogenesis is cata-
lyzed by acetyl-CoA carboxylase (ACAC), a biotin-dependent
enzyme that irreversibly carboxylates acetyl-CoA to malonyl-
CoA (Brownsey et al., 2006). The reverse reaction (i.e., the decar-
boxylation of malonyl-CoA to acetyl-CoA), which is catalyzed by
malonyl-CoA decarboxylase (MLYCD), not only inhibits lipogen-
esis but also stimulates the mitochondrial uptake of free fatty
acids for b-oxidation by relieving the malonyl-CoA-mediated
inhibition of CPT1 (Koves et al., 2008). Interestingly, the mus-
cle-specific knockout of Mlycd prevents the development of
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(Koves et al., 2008). The human genome codes for two ACAC
isoforms, namely ACACA and ACACB, which are differentially
expressed in distinct tissues (Travers and Barber, 1997). In
energy-low conditions (low ATP, high cyclic AMP levels), ACAC
is inhibited upon phosphorylation by protein kinase, AMP-acti-
vated (PRKA, best known as AMPK). In line with this notion,
the cytosolic pool of acetyl-CoA increases upon AMPK activa-
tion, at least in yeast (Zhang et al., 2013). Whether a similar effect
occurs in mammalian cells remains to be confirmed. In mouse
hepatocytes, the knockout of both Acaca and Acacb causes
the hyperacetylation of extramitochondrial proteins (but the hy-
poacetylation of mitochondrial proteins) (Chow et al., 2014), sug-
gesting that the utilization of acetyl-CoA for lipogenesis has a
significant impact on acetylation reactions. Spermidine/sper-
mine N(1)-acetyltransferase 1 (SAT1) also consumes cytosolic
acetyl-CoA as it acetylates polyamines (i.e., spermidine and
spermine) to facilitate their secretion from cells and in fine their
excretion with urine (Pegg, 2008). This pathway may be impor-
tant for increasing energy expenditure upon inhibition of nicotin-
amide N-methyltransferase (NNMT) in adipocytes (Kraus et al.,
2014). Extramitochondrial variants of the acetyl-CoA thiolase
complex and HMGCS (i.e., HMGCS1) employ three acetyl-
CoA molecules to synthesize 3-hydroxy-3-methyglutaryl-CoA
(HMGC) (Edwards and Ericsson, 1999). Whereas mitochondrial
HMGC generally feeds the synthesis of ketone bodies, its cyto-
solic counterpart is metabolized by 3-hydroxy-3-methyl-glu-
taryl-CoA reductase (HMGCR, the pharmacological target of
statins) within the mevalonate pathway, which is essential in all
cells for the production of sterols, ubiquinone (coenzyme Q10),
heme A, and other isoprenoids (Edwards and Ericsson, 1999).
Finally, cytosolic acetyl-CoA is required for cell type-specific
metabolic circuitries, such as the synthesis of acetylcholine,
implying that the survival and activity of cholinergic neurons
are particularly dependent on acetyl-CoA (Szutowicz et al.,
2013).
Peroxisomal Metabolism of Acetyl-CoA in Yeast
The peroxisomal metabolism of acetyl-CoA has not been studied
in detail in the mammalian system (Chen et al., 2012). In yeast,
b-oxidation underlies the synthesis of a significant fraction of
the peroxisomal acetyl-CoA pool (Choudhary et al., 2014). In
addition, yeast cells can produce acetyl-CoA within peroxi-
somes directly from acetate, a CoA-dependent reaction cata-
lyzed by acetate-CoA ligase 1 (Acs1) (Chen et al., 2012). Finally,
yeast cells employ the majority of peroxisomal acetyl-CoA to
feed the glyoxylate cycle, a metabolic circuitry that generates
succinate for carbohydrate synthesis (Kunze et al., 2006). Of
note, recent data suggest that (at least some) human tissues
may be endowed with enzymatic activities that are required
for the glyoxylate cycle, such as the ability to reversibly convert
acetyl-CoA, glyoxylate, and H2O into malate and CoA (Strittmat-
ter et al., 2014). Nonetheless, the glyoxylate cycle is still consid-
ered as an anabolic pathway operating in lower organisms only.
Compartmentalization of Acetyl-CoA Metabolism
Acetyl-CoA exists in separate mitochondrial, peroxisomal,
nucleo-cytosolic, and intrareticular pools (Figure 2). Indeed, the
inner mitochondrial, peroxisomal, and reticular membranes
are impermeant to the highly charged acetyl-CoA molecule.Conversely, nuclear pores allow acetyl-CoA to freely distribute
between the cytosol and the nucleus. Of note, the endoplasmic
reticulum (ER) does not contain acetyl-CoA-generating en-
zymes, implying that the acetylation of proteins within the ER
lumen critically depends on the import of acetyl-CoA from the
cytosol. Taken together, these observations suggest that the
bioenergetic and signaling functions of acetyl-CoA are finely
regulated by compartmentalization and inter-organellar acetyl-
CoA fluxes, which (at least in part) are influenced by the subcel-
lular localization of acetyl-CoA-generating reactions.
Export of Acetyl-CoA from Mitochondria
The transport of acetyl-CoA from the mitochondrial matrix to the
cytosol heavily relies on the so-called ‘‘citrate-malate-pyruvate
shuttle.’’ In this context, mitochondrial acetyl-CoA is condensed
with oxaloacetate by citrate synthase (CS), the first enzyme of
the TCA cycle, generating citrate and free CoA. Citrate can be
exported to the cytosol through SLC25A1 (also known as citrate
carrier), followed by the regeneration of oxaloacetate and acetyl-
CoA upon the ATP- and CoA-dependent reaction catalyzed by
ACLY (Zaidi et al., 2012). Cytosolic oxaloacetate is the substrate
of malate dehydrogenase 1, NAD (soluble) (MDH1), catalyzing
the NADH-dependent synthesis of malate, which can be trans-
ported back to the mitochondrial matrix via solute carrier family
25 (mitochondrial carrier; dicarboxylate transporter), member 10
(SLC25A10), an inorganic phosphate/dicarboxylate antiporter
(Mizuarai et al., 2005), or solute carrier family 25 (mitochondrial
carrier; oxoglutarate carrier), member 11 (SLC25A11), an a-keto-
glutarate/malate antiporter (Wallace, 2012). Alternatively, malic
enzyme 1, NADP(+)-dependent, cytosolic (ME1) can convert
malate into pyruvate, which can re-enter the mitochondrial
matrix via the MPC (Bender et al., 2015). Acetyl-CoA is also ex-
ported frommitochondria via the carnitine shuttle. As mentioned
above, fatty acids enter mitochondria in the form of acylcarnitine
via the antiporter SLC25A20, which generally exchanges them
with free L-carnitine (Rebouche and Seim, 1998). Mitochondrial
L-carnitine can also be converted by carnitine O-acetyltransfer-
ase (CRAT) into acetyl-L-carnitine, and the latter shares with free
L-carnitine the ability to drive the SLC25A20 antiporter. Finally,
cytosolic acetyl-L-carnitine can regenerate acetyl-CoA and
L-carnitine via the CoA-dependent reaction catalyzed by a
cytosolic variant of CRAT (Madiraju et al., 2009). Thus, the cit-
rate-malate-pyruvate and the carnitine shuttle may ensure the
continuous transfer of acetyl-CoA from mitochondria to the
cytosol. Of note, the enzymatic activity of CRAT in skeletal mus-
cles appears to be critical for whole-body glucose tolerance and
metabolic fitness (Muoio et al., 2012). Most likely, this reflects the
ability of CRAT to drive the export of excess acetyl-CoA from the
mitochondrial matrix, hence preventing PDC substrate inhibition
(Muoio et al., 2012). Taken together with the data obtained with
muscle-specificMlycd–/– mice (Koves et al., 2008), these obser-
vations connect insulin (INS) resistance with a situation of mito-
chondrial overload characterized by excess b-oxidation and high
acetyl-CoA levels.
The acetyl-CoA concentration gradient across the inner
mitochondrial membrane is influenced not only by the rate of
acetyl-CoA synthesis and consumption in the cytosol and within
mitochondria, but also by the activity of: (1) the citrate carrier
(SLC25A1), which can be increased by pro-inflammatory tran-
scription factors like NF-kB and signal transducer and activatorCell Metabolism 21, June 2, 2015 ª2015 Elsevier Inc. 809
Figure 2. Compartmentalization of Acetyl-CoA Metabolism
The subcellular fluxes of acetyl coenzyme A (acetyl-CoA) are tightly regulated. Two multicomponent systems ensure the exchange of acetyl-CoA between the
nucleo-cytosolic compartment and mitochondria: the so-called ‘‘carnitine shuttle’’ and the so-called ‘‘citrate-malate-pyruvate shuttle.’’ The former plays a key
role in b-oxidation and branched-chain amino acid (BCAA) mitochondrial catabolism, as it allows cytosolic acyl-CoA (derived from free fatty acids, FFAs) and
a-ketoacids (derived from BCAAs) to enter the mitochondrial matrix upon conjugation with L-carnitine. The actual import of these species into mitochondria is
coupled to the export of L-carnitine or acetyl-L-carnitine, and acetyl-L-carnitine can bemetabolized by a cytosolic variant of carnitine O-acetyltransferase (CRAT)
to generate acetyl-CoA (and free L-carnitine). The latter allows for the exchange of several metabolic intermediates between the cytosol and mitochondria,
including citrate, oxaloacetate, a-ketoglutarate, glutamate, and aspartate. In doing so, the citrate-malate-pyruvate shuttle provides substrates for anabolic
metabolism (in energy-high conditions) or supports bioenergetic metabolism (in energy-low conditions). AT1 (official name SLC33A1) is responsible for the import
of acetyl-CoA into the endoplasmic reticulum (ER) lumen. a-KG, a-ketoglutarate; ACLY, ATP citrate lyase; AGC, aspartate/glutamate carrier (SLC25A13); Asp,
aspartate; CACT, carnitine/acylcarnitine translocase (SLC25A20); Cit, citrate; CS, citrate synthase; CTP, citrate transporter (SLC25A1); DIC, dicarboxylate carrier
(SLC25A10); Glu, glutamate; GLUD1, glutamate dehydrogenase 1; GLUD2, glutamate dehydrogenase 2; GOT1, glutamic-oxaloacetic transaminase 1, soluble;
GOT2, glutamic-oxaloacetic transaminase 2, mitochondrial; Mal, malate; MDH1, malate dehydrogenase 1, NAD (soluble); MDH2, malate dehydrogenase 2, NAD
(mitochondrial); ME1, malic enzyme 1, NADP(+)-dependent, cytosolic; MPC1, mitochondrial pyruvate carrier 1; MPC2, mitochondrial pyruvate carrier 2; OAA,
oxaloacetate; OGC, oxoglutarate carrier (SLC25A11); PDC, pyruvate decarboxylase; Pi, inorganic phosphate; Pyr, pyruvate.
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Reviewof transcription 1 (STAT1) (Infantino et al., 2014); and (2) ACLY,
which is regulated by several signal transducers, including Kirs-
ten rat sarcoma viral oncogene homolog (KRAS) and v-akt
murine thymoma viral oncogene homolog 1 (AKT1) (Berwick
et al., 2002; Lee et al., 2014). Of note, the export of citrate from
mitochondria creates the need for the anaplerotic replenishment
of TCA cycle intermediates that regenerate oxaloacetate, mean-
ing that the extracellular availability of glutamine and the
metabolic flux through glutaminolysis also influence the relative
abundance of mitochondrial and cytosolic acetyl-CoA (Yang
et al., 2014). Finally, acetyl-CoA might be non-specifically
released from the mitochondrial matrix upon transient openings
of the so-called ‘‘permeability transition pore complex,’’ a multi-
component channel built across the inner and outer mitochon-
drial membranes permeant to solutes < 1.5 kDa and involved
in the regulation of cell death (Galluzzi et al., 2015a). This
possible mechanism of acetyl-CoA release has not been investi-
gated in detail thus far.810 Cell Metabolism 21, June 2, 2015 ª2015 Elsevier Inc.Export of Acetyl-CoA from Peroxisomes
In yeast cells, peroxisomal acetyl-CoA can be exported to the
nucleo-cytosolic compartment by at least two distinct mecha-
nisms: (1) via a carnitine shuttle, relying on the generation of
peroxisomal acetyl-L-carnitine by the yeast ortholog of CRAT
(Franken et al., 2008); and (2) in the form of succinate, one of
the products of the glyoxylate cycle (which consumes acetyl-
CoA) (Kunze et al., 2006). Of note, the release of succinate
does entail a reduction in peroxisomal pool acetyl-CoA, but not
a direct increase in its nucleo-cytosolic counterpart.
Import of Acetyl-CoA into the Endoplasmic Reticulum
The transfer of acetyl-CoA from the cytosol to the ER lumen is
mediated by solute carrier family 33, member 1 (SLC33A1, also
known as AT1) (Kanamori et al., 1997), a protein that is mutated
in spastic paraplegia 42, an autosomal dominant neurodegener-
ative disease characterized by muscle wasting and progressive
weakness of the inferior limbs (Lin et al., 2008). Importantly,
SLC33A1 is transactivated by X-box binding protein 1 (XBP1),
Cell Metabolism
Reviewan ER stress-responsive factor (Damiano et al., 2015). Thus,
reticular acetyl-CoA levels are expected to increase (at the
expense of the nucleo-cytosolic pool) in the course of ER stress
responses (Galluzzi et al., 2014). In the ER lumen, acetyl-CoA is
the substrate of a few acetyltransferases including members of
the N-acetyltransferase 8 (NAT8) protein family and calreticulin
(CALR, a chaperone with acetyltransferase enzymatic activity)
(Ding et al., 2014). Acetylation reactions in the ER lumen may
allow correctly folded proteins to progress to the Golgi appa-
ratus for secretion, implying that the reticular pool of acetyl-
CoA could play an important role in protein quality control (Pehar
and Puglielli, 2013). Interestingly, N-acetyltransferase 8-like
(NAT8L) is specifically expressed by neurons, where it plays a
key role as it catalyzes the synthesis of N-acetylaspartate, the
most prominent storage and transport form of acetyl groups in
the brain (Moffett et al., 2013).
Compartmentalized Regulation of Protein Acetylation
The compartmentalization of acetyl-CoA pools has a major
impact on protein acetylation, be it non-enzymatic or be it cata-
lyzed by NATs or KATs. The rate of non-enzymatic acetylation,
which presumably relies on the highly reactive intermediate
acetyl-phosphate (functioning as the donor of acetyl groups), is
strongly influenced by the physicochemical properties of the
microenvironment (Kuhn et al., 2014). This implies that intracel-
lular pH gradients, such as the one built across the inner mito-
chondrial membrane by respiratory chain complexes I–IV, may
influence acetylation reactions (Wagner and Payne, 2013). More-
over, spermidine can compete with acetyl-CoA for binding to
EP300 (and perhaps other acetyltransferases), hence increasing
the acetyl-CoA concentration required for optimal acetyltrans-
ferase activity (Pietrocola et al., 2015). Since spermidine levels
vary in different organelles (Casero and Marton, 2007), this phe-
nomenonmay contribute to the compartmentalized regulation of
protein acetylation. Specific acetyltransferases and deacety-
lases are also subjected to subcellular compartmentalization.
This applies, for instance, to EP300 as well as to the deacetylase
SIRT1, both of which shuttle between the nucleus and the
cytosol (Chang and Guarente, 2014). Another deacetylase of
the sirtuin family, i.e., SIRT3, localizes for the most part to the
mitochondrial matrix, and its expression levels have been corre-
lated with differential patterns of mitochondrial protein acetyla-
tion both in baseline conditions (Dittenhafer-Reed et al., 2015)
and in the course of chronic caloric restriction (Hebert et al.,
2013). Importantly, the deacetylase activity of sirtuins obligatorily
relies on NAD+ as a cofactor, establishing yet another link be-
tween metabolism and protein acetylation levels.
Fluctuations of Acetyl-CoA Levels
At odds with ATP levels, which are relatively stable (to support
bioenergetic homeostasis), the abundance of acetyl-CoA fluctu-
ates in response toboth intracellular andextracellular cues. Thus,
acetyl-CoA levels have been shown to vary even in the course of
embryonic development (Tsuchiya et al., 2014). Unfortunately,
however, acetyl-CoA is generally quantified in whole-cell or
whole-organ extracts, and very few studies have measured
changing acetyl-CoA concentrations at the subcellular level.
Changing Acetyl-CoA levels in Cultured Cells
When human cancer cells are switched from normal culture me-
dia to serum- and nutrient-free conditions, intracellular acetyl-CoA levels fall well before the concentration of ATP and NADH
diminishes. Such a drop is more pronounced in the cytosolic
fraction than in whole-cell extracts, suggesting (but not demon-
strating unequivocally) that the mitochondrial pool of acetyl-CoA
is less susceptible to variations than it nucleo-cytosolic counter-
part (Marin˜o et al., 2014). The reduction in intracellular acetyl-
CoA levels can be detected as early as 30 min after the
switch of culture conditions and can be avoided by providing
various acetyl-CoA precursors, including dimethyl-a-ketogluta-
rate (a cell-permeant form of a-ketoglutarate), leucine or its de-
rivative a-ketoisocaproic acid, pyruvate, and PDC stimulators
(like lipoic acid and DCA) (Marin˜o et al., 2014). Conversely,
when cancer cells are cultured in rich media, various selective
manipulations of acetyl-CoA metabolism effectively can reduce
intracellular acetyl-CoA levels. These interventions include the
pharmacological or genetic inhibition of the MPC heterodimer,
CPT1, the BCKD complex, the citrate carrier (SLC25A1),
ACLY, and ACSS2 (Marin˜o et al., 2014). Thus, all these pathways
appear to contribute to the maintenance of optimal acetyl-CoA
levels, at least in human malignant cells cultured in standard
conditions.
Also, oncogenes may affect acetyl-CoA concentrations. The
overexpression of the anti-apoptotic protein BCL2-like 1
(BCL2L1, best known as BCL-XL) appears to reduce the
amounts of citrate, acetyl-CoA, and Na-acetylated proteins in
the cytoplasm, and this would etiologically contribute to onco-
genesis (Yi et al., 2011). To the best of our knowledge, however,
this report has not been confirmed by independent investigators
yet. The knockout of Myc in rat fibroblasts results in decreased
acetyl-CoA levels (Edmunds et al., 2014), corroborating the
notion that Myc family members normally stimulate mitochon-
drial acetyl-CoA production (and histone acetylation) (Morrish
et al., 2010). Similar observations (i.e., increased acetyl-CoA/
CoA ratio and/or histone acetylation levels) have been made:
(1) upon the transgenic expression of a myristoylated, constitu-
tively active variant of AKT1 (myrAKT1) in cultured human glio-
blastoma cells; (2) upon the constitutive expression of oncogenic
KRAS, stimulating accrued AKT1 signaling, in pancreatic cells
in vivo; as well as (3) following the doxycycline-inducible expres-
sion of myrAKT1 in mammary epithelial cells in vivo (Lee et al.,
2014). At least in part, the ability of AKT1 to promote the accumu-
lation of acetyl-CoA originates from its ability to phosphorylate
ACLY on S455, hence stimulating its catalytic activity (Lee
et al., 2014). These data lend further support to the notion that
increased levels of acetyl-CoA and acetylated histones may be
required to sustain the accelerated proliferation of cancer cells.
Changing Acetyl-CoA Levels In Vivo
Mice deprived of food (but with access to water ad libitum) for
24 hr exhibit a significant reduction in total acetyl-CoA levels in
several organs, including the heart and muscles, corresponding
to a decrease in protein acetylation levels (Marin˜o et al., 2014).
However, the same experimental conditions have no major
effects on acetyl-CoA concentrations in the brain (Marin˜o
et al., 2014) and actually increase hepatic acetyl-CoA and
protein acetylation levels (Chow et al., 2014). This latter phenom-
enon has been causally linked to the mobilization of subcutane-
ous fat stores, one of the first effects of short-term fasting
(Browning et al., 2012). In fasting conditions, indeed, fatty acids
are released by adipocytes and employed (at least in part) asCell Metabolism 21, June 2, 2015 ª2015 Elsevier Inc. 811
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patocytes (which are particularly rich in mitochondria) (Browning
et al., 2012). Repeated intraperitoneal injections of dimethyl-
a-ketoglutarate or dichloroacetate (DCA) efficiently prevent the
drop of acetyl-CoA levels provoked by starvation in the heart
and muscle of mice (Marin˜o et al., 2014). Along similar lines,
the provision of excess acetate has been shown to increase
acetyl-CoA levels in the hypothalamus upon the activation of
ACAC, eventually resulting in the synthesis of anorectic neuro-
peptides and appetite suppression (Frost et al., 2014). Finally,
ethanol intake augments acetyl-CoA levels in hepatic mitochon-
dria (Fritz et al., 2013).
The aforementioned findings indicate that alterations in food
and alcohol intake have a direct impact on intracellular acetyl-
CoA levels. However, it appears unlikely that the starvation-
induced decrease of acetyl-CoA in the heart and muscles solely
and directly results from reduced glucose availability. Indeed,
intracellular acetyl-CoA concentrations drop well before glyce-
mia decreases, at the same time as circulating triglycerides in-
crease. This phenomenon may therefore reflect the ability of
starvation to cause a diminution in the plasma levels of various
cytokines and growth factors, including INS and insulin-like
growth factor 1 (IGF1), coupled to an increase in the circulating
amounts of the IGF1 antagonist insulin-like growth factor binding
protein 1 (IGFBP1) (Cheng et al., 2014). Limited growth factor
signaling results indeed in reduced AKT1 activation, which has
(at least) two negative consequences for acetyl-CoA meta-
bolism. First, AKT1 signaling is required for normal glucose up-
take through plasma membrane glucose transporters (Wieman
et al., 2007). Second, AKT1 normally phosphorylates ACLY on
S455, hence stimulating acetyl-CoA production (Lee et al.,
2014). Although this hypothetical pathway linking starvation to
dwindling acetyl-CoA levels has not been formally explored
in vivo, signs of AKT1 activation (i.e., AKT1 phosphorylation on
S473) positively correlate with histone acetylation levels in hu-
man gliomas and prostate cancers (Lee et al., 2014). Another
major pathway that may link starvation to dropping acetyl-CoA
levels in some cells involves SIRT1, which is activated in en-
ergy-low conditions (high NAD+ levels) (Morselli et al., 2010)
and inhibits ACSS2 (Sahar et al., 2014). This latter effect may
explain the circadian rhythmicity of hepatic acetyl-CoA levels
in mice (Sahar et al., 2014). Finally, some tissuesmay experience
intracellular acetyl-CoA depletion in response to organismal
starvation as a consequence of limited glutamine availability, at
least hypothetically (Pozefsky et al., 1976). This possibility awaits
experimental verification. Irrespective of this open issue, it
seems likely that several mechanisms operating in parallel con-
nect organismal starvation with the decrease in intracellular
acetyl-CoA levels observed in some tissues.
Obviously, metabolic disorders also affect acetyl-CoA con-
centrations. For example, type 1 diabetes causes a major in-
crease in hepatic acetyl-CoA concentrations (Perry et al.,
2014). Interestingly, this effect can be mimicked by a 3-day
high-fat dietary regimen combined with an artificial elevation of
circulating corticosterone levels (which occur spontaneously in
animal models of type 1 diabetes) and can be reverted by the
administration of mifepristone, an antagonist of glucocorticoid
receptors (Perry et al., 2014). Thus, the increased turnover of
fatty acids and acetate associated with type I diabetes may812 Cell Metabolism 21, June 2, 2015 ª2015 Elsevier Inc.elevate mitochondrial acetyl-CoA levels, ultimately promoting
hepatic gluconeogenesis by virtue of its capacity to allosterically
activate PC and inhibit the PDC. Further supporting this notion,
mice genetically endowed with a muscle-specific defect in
b-oxidation are significantly less prone to develop diet-induced
INS resistance than their wild-type counterparts (see above)
(Koves et al., 2008).
Acetyl-CoA and Gene Expression
In multiple cell types, histone acetylation is highly sensitive to the
availability of acetyl-CoA (Cai et al., 2011; Donohoe et al., 2012;
Lee et al., 2014; Moussaieff et al., 2015; Takahashi et al., 2006;
Wellen et al., 2009). Acetyl-CoA is indeed the obligate cofactor
for histone acetyltransferases (HATs), meaning that the abun-
dance of the nucleo-cytosolic pool may have a direct impact
on the enzymatic activity of HATs, especially those with a rela-
tively high KD for acetyl-CoA. Thus, drops in nucleo-cytosolic
acetyl-CoA levels below the KD of specific HATs may directly
reduce their activity. Moreover, several HATs including GCN5
are subjected to product inhibition by free CoA (Tanner et al.,
2000). This indicates that the acetyl-CoA/CoA ratio may be the
relevant regulator of the enzymatic activity of HATs, rather than
the absolute levels of acetyl-CoA (Lee et al., 2013). Irrespective
of the underlying mechanisms, this establishes a direct link be-
tween the nucleo-cytosolic abundance of acetyl-CoA and the
epigenetic control of gene expression. Indeed, high levels of his-
tone acetylation are required not only to support global tran-
scription (Moussaieff et al., 2015; Takahashi et al., 2006), but
also for the preferential transactivation of genes involved in cell
growth and replication (Cai et al., 2011; Donohoe et al., 2012;
Lee et al., 2014; Shi and Tu, 2013), glycolysis (Wellen et al.,
2009), and resistance to oxidative stress (Shimazu et al., 2013).
Fluctuations in metabolites other than acetyl-CoA also affect
histone acetylation, hence impacting transcription both quantita-
tively and qualitatively. Besides feeding the TCA (and hence
stimulating the synthesis of acetyl-CoA) (Donohoe et al., 2012),
D-b-hydroxybutyrate inhibits HDAC1, HDAC2, and HDAC3 (Shi-
mazu et al., 2013). Along similar lines, L-carnitine and sphingo-
sine-1-phosphate favor histone acetylation by operating as
HDAC1 and HDAC2 inhibitors (Hait et al., 2009; Huang et al.,
2012). Conversely, increases in the NAD+/NADH ratio (which
accompany starvation) promote histone deacetylation by stimu-
lating the activity of sirtuins (Guarente, 2013). Also variations in
intracellular pH (pHi) have a major impact on histone acetylation.
Intracellular acidification (i.e., decreased pHi) promotes the ac-
tivity of histone deacetylases (as well as the export of protonated
acetate via monocarboxylate transporter as a pHi buffer mecha-
nism), whereas intracellular alkalinization (i.e., increased pHi)
augments global histone acetylation (McBrian et al., 2013).
Thus, histone acetylation appears to function as a rheostat to
regulate pHi. Of note, the chromatin of mammalian cells contains
at least 109 potential acetylation sites, meaning that massive his-
tone acetylation may cause a sizeable depletion of the nucleo-
cytosolic acetyl-CoA pool, hence impacting cellular metabolism.
Conversely, the acetyl residues stored in histones may be mobi-
lized to generate acetate as an energy source (Martinez-Pastor
et al., 2013). All these examples underscore the intricate links be-
tween metabolism and histone acetylation levels, which in turn
influence gene expression both quantitatively and qualitatively.
Figure 3. Impact of the Acetyl-CoA/CoA Ratio on Global Cellular Functions
The relative abundance of acetyl coenzyme A (acetyl-CoA) and coenzyme A (CoA) controls various cellular processes, including cell growth and mitosis,
regulated cell death (RCD), and autophagy. For instance, elevated acylation levels of histones, transcription factors (TFs), and various enzymes have been
associated with intensive growth and proliferation. The pro-apoptotic activity of caspase-2 (CASP2), which appears to require Na-acetylation, is controlled upon
physical sequestration by 14-3-3z, and this inhibitory interaction is promoted by the calcium/calmodulin-dependent protein kinase II (CAMK2)-dependent
phosphorylation of CASP2 as well as by the sirtuin 1 (SIRT1)-dependent deacetylation of 14-3-3z (two processes that are favored by low acetyl-CoA/CoA ratios).
Finally, the accumulation of CoA at the expense of acetyl-CoA favors the SIRT1- and E1A binding protein p300 (EP300)-dependent deacetylation of various ATG
proteins, promotes the activation of AMPK, and inhibits v-akt murine thymoma viral oncogene homolog 1 (AKT1) signaling, globally stimulating the autophagic
flux. HAT, histone acetyltransferase; KAT, lysine acetyltransferase; MTORCI, mechanistic target of rapamycin complex I; NAT, Na acetyltransferase; ULK1, unc-
51-like autophagy activating kinase 1.
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modulate gene expression by altering the acetylation state of
transcription factors. Thus, acetate stimulates erythropoiesis in
multiple mouse models of anemia by activating a signaling
pathway that involves (1) the conversion of acetate into acetyl-
CoA (by ACSS2); (2) the acetylation of endothelial PAS domain
protein 1 (EPAS1) by CBP; and (3) the recruitment of a transcrip-
tionally active EPAS1-containing complex to the promoter of the
gene encoding erythropoietin (Xu et al., 2014). Other prominent
transcription factors that are regulated by CBP- or EP300-
dependent acetylation as well as by SIRT1- or HDAC1-mediated
deacetylation are forkhead box O (FOXO) proteins (van der Horst
and Burgering, 2007) and tumor protein p53 (TP53) (Xu, 2003).
FOXO1 plays an important role in linking caloric restriction to life-
span extension in several model organisms (Kim et al., 2015).
TP53 is a key regulator of homeostasis in physiological and path-
ological conditions, and its activity is controlled by several post-
translational modifications, including acetylation at multiple (at
least seven) lysine residues (Tang et al., 2008). Besides EP300
and CBP, at least four other KATs can acetylate TP53, namely,
KAT2B (also known as PCAF), KAT6A (also known as MOZ),
KAT5 (also known as TIP60), and KAT8 (also known as MOF).
Acetylation opens the conformation of TP53, alters its ability to
bind specific response elements on DNA, and generally in-
creases its transcriptional activity (Tang et al., 2008). Of note,the enzymatic activity of CBP responds to physiological varia-
tions in acetyl-CoA levels, at least in some cell types (Xu et al.,
2014). It has not yet been demonstrated whether this holds
true for other KATs operating on transcription factors. In spite
of this uncertainty, these examples illustrate the broad effects
of (de)acetylation reactions on the control of gene expression.
Acetyl-CoA and Cellular Anabolism versus Catabolism
Increased nucleo-cytosolic acetyl-CoA levels shift cellular meta-
bolism toward anabolic reactions as they shut off catabolic cir-
cuitries. This effect is not limited to basic biochemical circuitries,
but involves complex cellular (and organismal) programs. Thus,
acetyl-CoA levels affect the propensity of cells to grow, progress
along the cell cycle, mount autophagic responses to stress, and
succumb to RCD (Figure 3). In addition, the abundance of acetyl-
CoA in defined cell types influences the metabolic relationship
between different organs, as well as behavioral cues such as
appetite control.
Cell Growth and Mitosis
By favoring histone acetylation, elevated acetyl-CoA levels stim-
ulate the expression of multiple genes that are required for cell
growth and proliferation (Cai et al., 2011; Donohoe et al., 2012;
Lee et al., 2014; Shi and Tu, 2013; Wellen et al., 2009). In yeast,
the Acs1-dependent synthesis of acetyl-CoA does not only sup-
port global transcription, but it also allows for the preferentialCell Metabolism 21, June 2, 2015 ª2015 Elsevier Inc. 813
Cell Metabolism
Reviewtransactivation of various genes involved in cell growth and repli-
cation, like those encoding cyclin CLN3, several ribosomal sub-
units, and glycolytic enzymes (Cai et al., 2011; Shi and Tu, 2013).
In contrast, when yeast cells enter the stationary phase during
the so-called ‘‘diauxic shift’’ (i.e., the transition of cultured yeast
from a fermentative to a respiratory metabolism), acetyl-CoA
levels and global histone acetylation decrease. In this context,
a minority of so-called histone hypoacetylation-activated genes
(which are repressed during the exponential growth phase)
become activated (Mehrotra et al., 2014). In the mammalian sys-
tem, high acetyl-CoA concentrations also favor cell growth and
replication at the expenses of differentiation (Moussaieff et al.,
2015; Shan et al., 2014; Sutendra et al., 2014). Embryonic
stem cells quickly lose pluripotency along with a metabolic shift
involving decreased glycolytic activity, lowered acetyl-CoA
availability, and histone deacetylation (Moussaieff et al., 2015).
In line with this notion, artificially preserving acetyl-CoA levels
though the exogenous supply of acetate efficiently delays
embryonic stem cell differentiation as it preserves histone acet-
ylation (Moussaieff et al., 2015). Cancer cells, which are charac-
terized by increased proliferation rates, ectopically synthesize
acetyl-CoA in the nucleus (perhaps in an S phase-specific
manner), resulting in increased histone acetylation levels
(Comerford et al., 2014; Sutendra et al., 2014; Takahashi et al.,
2006; Wellen et al., 2009). Transcriptomic studies revealed that
a significant proportion of the genes that are responsive to
acetyl-CoA (and hence histone acetylation) levels are involved
in DNA replication, cell cycle progression, and general anabo-
lism (Lee et al., 2014). Of note, the acetylation of phosphogluco-
nate dehydrogenase (PDG) by a cytosolic variant of DLAT and
acetyl-CoA acetyltransferase 2 (ACAT2) augments its enzymatic
activity, hence promoting cellular anabolism as a consequence
of an increased metabolic flux through the pentose phosphate
pathway (PPP) (Shan et al., 2014). Altogether, these ob-
servations suggest that increased acetyl-CoA concentrations
promote cell growth and replication via transcriptional and
non-transcriptional mechanisms.
Catabolism and Autophagy
The depletion of nucleo-cytosolic acetyl-CoA activates AMPK
and inhibits the mechanistic target of rapamycin (MTOR) com-
plex I (MTORCI), hence arresting anabolic reactions and stimu-
lating autophagy (Galluzzi et al., 2015b; Marin˜o et al., 2014).
Histone deacetylation caused by the shortage of acetyl-CoA
favors the expression of pro-autophagic genes (Eisenberg
et al., 2014), whereas cytoplasmic deacetylation reactions acti-
vate various proteins that are required for autophagy (Marin˜o
et al., 2014). In line with this notion, replenishing the nucleo-cyto-
solic pool of acetyl-CoA by the microinjection of acetyl-CoA into
cultured human cells or by the systemic administration of di-
methlyl-a-ketoglutarate to mice suppresses starvation-induced
autophagy (Marin˜o et al., 2014). In human cells, low acetyl-
CoA levels restrain the enzymatic activity of EP300, and epistatic
analyses suggest that the inhibition of EP300 is largely respon-
sible for autophagy induction in these conditions (Marin˜o et al.,
2014). Various proteins of the autophagic machinery, including
ATG5, ATG7, and ATG12, are acetylated (and hence inhibited)
by EP300 or deacetylated (and hence activated) by SIRT1
(Madeo et al., 2014) Moreover, microtubule-associated protein
1 light chain 3 (MAP1LC3, best known as LC3) is deacetylated814 Cell Metabolism 21, June 2, 2015 ª2015 Elsevier Inc.by SIRT1 in the nucleus, allowing it to shuttle back to the cyto-
plasm (in complex with tumor protein p53 inducible nuclear
protein 2, TP53INP2) and participate in the assembly of autopha-
gosomes (Huang et al., 2015). ATG9A, a protein that shuttles
between the juxta-nuclear trans-Golgi compartment and late en-
dosomes, must also be deacetylated for autophagy to proceed
normally (Pehar et al., 2012). In line with this notion, loss-of-func-
tion mutations of SLC33A1, resulting in a depletion of reticular
acetyl-CoA, cause excessive autophagy (Peng et al., 2014).
The knockdown of biogenesis of lysosomal organelle com-
plex-1, subunit 1 (BLOC1S1, a mitochondrial KAT also known
as GCN5L1) favors the deacetylation of mitochondrial proteins
while stimulating mitophagy (Webster et al., 2013), an organ-
elle-specific type of autophagy targeting mitochondria (Green
et al., 2011). Beyond putative direct effects on mitochondria,
BLOC1S1 may control the activity of the pro-autophagic tran-
scription factor EB (TFEB) (Pietrocola et al., 2013). Bloc1s1/
mouse embryonic fibroblasts indeed exhibit increased expres-
sion levels of TFEB and its downstream targets (Scott et al.,
2014), providing yet another link between deacetylation and
the activation of a pro-autophagic transcriptional program.
These examples illustrate how the depletion of acetyl-CoA in
distinct subcellular compartments can ignite autophagy via a
multipronged effect on various autophagy-regulatory processes.
Several inducers of autophagy, including (but not limited to)
caloric restriction and spermidine, have lifespan-extending
effects in variousmodel organisms, including yeast, worms, flies,
and mice (Madeo et al., 2014), as they lower global protein acet-
ylation levels (Marin˜o et al., 2014). Intriguingly, reduced levels of
Myc also increase the lifespan of flies (Greer et al., 2013) and
mice (Hofmann et al., 2015) and are associated with lowered
nucleo-cytosolic acetyl-CoA levels (Edmunds et al., 2014; Mor-
rish et al., 2010). Along similar lines, nucleo-cytosolic acetyl-
CoA metabolism has been genetically linked to autophagy
regulation and lifespan in yeast and Drosophila melanogaster
(Eisenberg et al., 2014). Yeast cells overexpressing the ortholog
of mammalian ACSS2 (i.e., Acs2p) indeed exhibit reduced
lifespan as compared to their wild-type counterparts. Moreover,
the brain-specific knockout of AcCoAS (the sole ortholog
of mammalian ACSS1 and ACSS2 in Drosophila) suffices
to extend fly lifespan (Eisenberg et al., 2014). It has not been
tested yet whether direct genetic manipulations of acetyl-CoA
metabolism may have lifespan-extending effects in mammals
as well. Moreover, it remains to be determined whether the
autophagy-inducing and antidiabetic effects of endurance
training (He et al., 2012) may be ultimately linked to decreased
mitochondrial protein acetylation levels, as it is the case for
rats selectively bred for a high running capacity (Overmyer
et al., 2015).
Regulated Cell Death
The acetyl-CoA/CoA ratio appears to influence the propensity
of cells to undergo regulated variants of cell death, including
caspase-dependent apoptosis and regulated necrosis (Green
et al., 2014). To mention one example, the acetyl-CoA/CoA ratio
appears to be involved in a complex system of regulation of
caspase-2 (CASP2), an apoptotic protease. CoA (but less so
acetyl-CoA) interacts with calcium/calmodulin-dependent pro-
tein kinase II (CAMK2), hence reducing its threshold for activa-
tion by Ca2+ ions (McCoy et al., 2013). Active CAMK2 can
(legend on next page)
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Table 1. Main Pharmacological Modulators of Acetyl-CoA Metabolism
Family Molecule Indication(s) Development Status References
ACAC inhibitors TOFA Metabolic disorders Preclinical Harwood, 2005
ACLY inhibitors BMS-303141 Cancer Preclinical Hatzivassiliou et al., 2005;
Madeo et al., 2014Hydroxycitrate Cancer, obesity Phase IV clinical development
SB-204990 Cancer Preclinical
ACSS2 inhibitors 1-(2,3-di(thiophen-2-yl)quinoxalin-
6-yl)-3-(2-methoxyethyl)urea
Cancer Preclinical Comerford et al., 2014;
Mashimo et al., 2014
CPT1 inhibitors Etomoxir Cardiac disorders Terminated Abozguia et al., 2006
Perhexiline Cardiac disorders Phase II clinical development
Trimetazidine Cardiac disorders Phase IV clinical development
CRAT inhibitors Mildronate Cardiac disorders Approved Makrecka et al., 2014
GLS inhibitors BC-839 Cancer Preclinical Dura´n et al., 2012
DON Cancer Preclinical
HDAC inhibitors Belinostat Cancer Phase II clinical development Falkenberg and Johnstone,
2014Parabinostat Cancer Phase III clinical development
Romidepsin Cancer Approved
Valproic acid Cancer Phase III clinical development
Vorinostat Cancer Approved
HMGCR inhibitors Statins Cancer, metabolic
disorders
Approved Brautbar and Ballantyne,
2011; Demierre et al., 2005
KAT inhibitors Anacardic acid Cancer Preclinical Harwood, 2005
C646 Cancer Preclinical
Curcumin Cancer, metabolic
disorders
Phase II clinical development
Garcinol Cancer Preclinical
MB-3 Cancer Preclinical
MPC inhibitors UK5099 Cancer Preclinical Marin˜o et al., 2014
PDC activators DCA Cancer
Metabolic disorders
Approved (for lactic acidosis) Galluzzi et al., 2013
PDC inhibitors CPI-613 Cancer Phase II clinical development Pardee et al., 2014
SIRT1 activators Resveratrol Aging, cancer,
metabolic disorders
Phase III clinical development Athar et al., 2007; Baur
and Sinclair, 2006
SRT1720 Aging, metabolic
disorders
Preclinical
SLC25A1 inhibitors 1,2,3-BTC Cancer Preclinical Aluvila et al., 2010
1,2,3-BTC, 1,2,3-benzenetricarboxylate; ACAC, acetyl-CoA carboxylase; ACLY, ATP citrate lyase; ACSS2, acyl-CoA synthetase short-chain family
member 2; CPT1, carnitine palmitoyltransferase 1; CRAT, carnitine O-acetyltransferase; DON, 6-diazo-5-oxo-L-norleucine; GLS, glutaminase;
HDAC, histone deacetylase; HMGCR, 3-hydroxy-3-methyl-glutaryl-CoA reductase; KAT, lysine acetyl transferase; MPC, mitochondrial pyruvate car-
rier; PDC, pyruvate dehydrogenase complex; SIRT1, sirtuin 1; TOFA, 5-(tetradecyloxy)-2-furoic acid).
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Reviewphosphorylate CASP2, which favors the inhibitory interaction of
the latter with tyrosine 3-monooxygenase/tryptophan 5-mono-
oxygenase activation protein, zeta (YWHAZ, best known as
14-3-3z) (Nutt et al., 2009). Moreover, SIRT1 can promote the
anti-apoptotic functions of 14-3-3z by deacetylating it, a reaction
that is also favored by the accumulation of CoA at the expenses
of acetyl-CoA (Andersen et al., 2011). Finally, the full-blown
apoptotic activity of CASP2 may rely on Na-acetylation (YiFigure 4. Expression Levels of Proteins Involved in Acetyl-CoA Metabo
(A and B) The expression levels of proteins that participate in acetyl coenz
from The Human Protein Atlas (http://www.proteinatlas.org/). Proteins were
and ‘‘transporters,’’ ‘‘acetyltransferases,’’ and ‘‘deacetylases’’ (B) and subjec
detected.
816 Cell Metabolism 21, June 2, 2015 ª2015 Elsevier Inc.et al., 2011), which is supported by high acetyl-CoA levels.
Thus, a decreased acetyl-CoA/CoA ratio would promote cell
survival by multiple mechanisms impinging on the activity of
CASP2. Of note, the phosphorylation of CASP2 by CAMK2 re-
quires NADPH, a key antioxidant (and co-enzymatic reducing
agent) mainly generated by the PPP (Galluzzi et al., 2013).
Hence, oxidative stress can stimulate cell death by releasing
CASP2 from inhibition by 14-3-3z (Nutt et al., 2009). Apparentlylism
yme A (acetyl-CoA) metabolism in the indicated cell types were retrieved
arbitrarily subdivided according to function in ‘‘metabolic enzymes’’ (A)
ted to hierarchical clustering. NA, not assessed; MED, medium; ND, not
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Reviewat odds with this notion, the activity of SIRT1 depends on NAD+,
which also accumulates in the course of oxidative stress
responses (Houtkooper et al., 2012). A model that reconciles
these findings is missing. Since CASP2 can be found both in
the nucleus and in the cytoplasm, subcellular compartmentaliza-
tion may play a hitherto unrecognized role in this process.
Irrespective of such a conundrum, these findings suggest a tight
link between acetyl-CoA metabolism, acetylation reactions,
and RCD.
Conclusions and Perspectives
Acetyl-CoA regulates several cellular processes as it controls the
balance between anabolic and catabolic reactions, both as a
central metabolic intermediate and as a signal transducer.
Perhaps only ATP and NADH share with acetyl-CoA such a
key position in cell biology. Indeed, acetyl-CoA not only is the
substrate, intermediate, or product of vital bioenergetic cir-
cuitries, but also regulates several enzymes allosterically and in-
fluences the activity of a wide panel of processes (including gene
expression) via (de)acetylation reactions. In this respect, three
features render acetyl-CoA unique, namely that (1) its abun-
dance dictates one of the quantitatively and functionally most
important post-translational modifications that affect eukaryotic
proteins, (2) it is subjected to a rigorous subcellular compartmen-
talization, adding refinement to its regulatory impact, and (3) its
concentration and subcellular fluxes are subjected to strong
quantitative changes upon variations in its synthesis and use.
Thus, acetyl-CoA levels in different subcellular compartments
may constitute an intracellular gauge of changing microenviron-
mental conditions and ultimately tune the cellular programs of
adaptation to such perturbations. In line with this latter notion,
the expression levels of proteins involved in acetyl-CoA meta-
bolism and transport, as well as in (de)acetylation reactions,
exhibit remarkable variations in cells of different histological
origin (Figure 4). Thus, the cellular differentiation and activation
state might also affect the relative abundance of multiple
acetyl-CoA-relevant enzymes, adding yet another layer of
complexity to this regulatory network.
Pharmaceutical agents that influence the acetyl-CoA meta-
bolism are being developed at an accelerating pace (Table 1).
Some HDAC inhibitors including suberanilohydroxamic acid
(SAHA, best known as vorinostat) and romidepsin are approved
by international regulatory agencies for use in cancer patients
(Falkenberg and Johnstone, 2014). Inhibitors of acetyl-CoA-
consuming enzymes like ACACs and KATs are in preclinical
development, mostly for the treatment of metabolic syndromes
(Harwood, 2005). The PDC-activating agent DCA is licensed
for the treatment of lactic acidosis (as it favors the mitochondrial
metabolism of pyruvate at the expense of cytosolic reduction to
lactate) and is being intensively investigated for its antineoplastic
activity (Galluzzi et al., 2013). Inhibitors of acetyl-CoA-generating
enzymes such as ACLY are in clinical development as weight
loss-promoting or anticancer agents (Hatzivassiliou et al.,
2005; Madeo et al., 2014). Along similar lines, ACSS2 inhibitors
have been proposed to mediate selective antineoplastic effects,
reflecting the dependency of malignant cells on acetate as
acetyl-CoA precursor (Comerford et al., 2014). The future will
tell whether these agents are associated with unsustainable tox-
icities due to their disruptive effects on acetyl-CoA metabolismor whether the plasticity of the acetyl-CoA regulatory network
can accommodate successful therapeutic interventions.
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